ACADIA Pharmaceuticals Inc. ((ACAD)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ACADIA Pharmaceuticals Inc. is conducting a Phase 3, Open-Label Extension Study titled ’52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)’. The study aims to evaluate the long-term safety and efficacy of ACP-204, a drug intended to treat psychosis in adults with Lewy Body Dementia. This study is significant as it addresses a critical need for effective treatments in this patient population.
The intervention being tested is ACP-204, an experimental drug administered as a 30 mg capsule taken orally once daily. The dosage may be adjusted to 60 mg if the initial efficacy is suboptimal, with the possibility of further titration based on patient response.
The study follows an interventional design with a single-group assignment. There is no masking involved, meaning all participants and researchers are aware of the treatment being administered. The primary purpose of the study is treatment-focused, aiming to assess the drug’s long-term impact on patients.
The study is set to begin on July 24, 2025, with the primary completion and estimated study completion dates yet to be announced. The last update was submitted on the same date, indicating the study is in the preparatory phase and not yet recruiting participants.
This study update could influence ACADIA Pharmaceuticals’ stock performance positively, as successful results may enhance the company’s market position in the treatment of Lewy Body Dementia Psychosis. Investors should monitor this study closely, considering the competitive landscape in neurodegenerative disease treatments.
The study is ongoing, with further details available on the ClinicalTrials portal.